SymBio Pharmaceuticals

About:

SymBio Pharmaceuticals develops therapeutic products for cancer, hematology, and autoimmune diseases.

Website: http://www.symbiopharma.com

Top Investors: Mitsubishi UFJ Capital, Mizuho Capital, SBI Group, DBJ Capital, JAFCO

Description:

SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan.

Total Funding Amount:

$746M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Tokyo, Tokyo, Japan

Founded Date:

2005-03-01

Founders:

Fuminori Yoshida

Number of Employees:

51-100

Last Funding Date:

2016-04-06

IPO Status:

Public

© 2025 bioDAO.ai